Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | RECQL | P46063 | 6/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.66 |
| ▸ | APEX1 | P27695 | 5/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | USP2 | O75604 | 4/20 | 0.66 |
| ▸ | BLM | P54132 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | GALK1 | P51570 | 3/20 | 0.66 |
| ▸ | THRB | P10828 | 2/20 | 0.66 |
| ▸ | CASP1 | P29466 | 2/20 | 0.66 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370989 | 1.00 | BCL2 (0.68) | BCL2KDM4EMAPTRECQLTDP1 | |
| SCHEMBL1674784 | 0.95 | BCL2 (0.75) | BCL2KDM4EMAPTRECQLTDP1 | |
| SCHEMBL28693828 | 0.87 | BCL2 (0.69) | BCL2KDM4EMAPTRECQLTDP1 | |
| SCHEMBL29350322 | 0.81 | BCL2 (0.94) | BCL2KDM4EMAPTRECQLTDP1 | |
| SCHEMBL29373670 | 0.81 | BCL2 (0.94) | BCL2KDM4EMAPTRECQLTDP1 | |
| SCHEMBL13300891 | 0.81 | BCL2 (0.94) | BCL2KDM4EMAPTRECQLTDP1 | |
| SCHEMBL12240726 | 0.81 | BCL2 (0.94) | BCL2KDM4EMAPTRECQLTDP1 | |
| SCHEMBL12792863 | 0.81 | BCL2 (0.94) | BCL2KDM4EMAPTRECQLTDP1 | |
| SCHEMBL14535256 | 0.81 | BCL2 (0.94) | BCL2KDM4EMAPTRECQLTDP1 | |
| SCHEMBL25937926 | 0.81 | BCL2 (0.94) | BCL2KDM4EMAPTRECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 926 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122004484-A | Method for synergistically increasing resistant starch by autoclave treatment and polyphenol | 湖南农业大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260020595-A1 | MOIST ORAL COMPOSITIONS | NICOVENTURES TRADING LTD (GB) | 2026-01-22 | — | — | US | claimed |
| US-12439952-B2 | Moist oral compositions | Nicoventures Trading Limited (GB) | 2025-10-14 | — | — | US | claimed |
| CN-119242733-A | Preparation method of extract containing theaflavin digallate | 江苏德和生物科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| EP-4373311-A1 | NANOEMULSION COMPRISING CANNABINOID AND/OR CANNABIMIMETIC | Nicoventures Trading Limited (GB) | 2024-05-29 | — | — | EP | claimed |
| CN-117607295-A | Screening method of key flavor substances for origin discrimination in CTC black tea | 安徽农业大学 | 2024-02-27 | — | — | CN | claimed |
| CN-117137142-A | Theaflavin compound and preparation method and application thereof | 西南大学 | 2023-12-01 | — | — | CN | claimed |
| CN-115181572-B | Application of theaflavin and composition thereof in reducing antibiotic resistance genes in soil | 浙江大学 | 2023-10-20 | — | — | CN | claimed |
| CN-116687910-A | Tea composition capable of regulating estrogen signal pathway and application thereof in preventing and treating neurodegenerative diseases | 湖南农业大学 | 2023-09-05 | — | — | CN | claimed |
| WO-2023159850-A1 | TEA COMPOSITION CAPABLE OF REGULATING ESTROGEN SIGNALING PATHWAY AND USE OF SAME IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | 湖南农业大学 | 2023-08-31 | — | — | WO | claimed |
| EP-0522502-A1 | Inhibitors of sucrase activity from tea | MITSUI NORIN CO., LTD. (JP) | 1993-01-13 | — | — | EP | claimed |
| US-5137922-A | METHOD FOR INHIBITING AND TREATING INFECTION CAUSED BY INFLUENZA VIRUS | MITSUI NORIN CO., LTD. (JP) | 1992-08-11 | — | — | US | claimed |
| US-5135957-A | Tea polyphenols; applying catechin compounds; fungicides | MITSUI NORIN CO., LTD. (JP) | 1992-08-04 | — | — | US | claimed |
| US-5104901-A | Orally administering tea polyphenol; theaflavin, catechin, epigallocatechin gallate | MITSUI NORIN CO., LTD. (JP) | 1992-04-14 | — | — | US | claimed |
| EP-0443090-A2 | Agent for preventing infection with methicillin-resistant staphylococcus | MITSUI NORIN CO., LTD. (JP) | 1991-08-28 | — | — | EP | claimed |
| EP-0423419-A1 | Inhibitive agent against activity of alpha-amylase | MITSUI NORIN CO., LTD. (JP) | 1991-04-24 | — | — | EP | claimed |
| EP-0417385-A2 | Preventive and curative medicament against infection with influenza virus, containing tea or tea polyphenols | MITSUI NORIN CO., LTD. (JP) | 1991-03-20 | — | — | EP | claimed |
| EP-0415126-A1 | Anti-dental plaque agents | MITSUI NORIN CO., LTD. (JP) | 1991-03-06 | — | — | EP | claimed |
| EP-0397914-A1 | Antitoxins for bacterial exotoxins | MITSUI NORIN CO., LTD. (JP) | 1990-11-22 | — | — | EP | claimed |
| US-4840966-A | ADMINISTERING EPIGALLOCATECHIN GALLATE, THEAFLAVIN. THEAFLAVIN MONO(DI)GALLATE | MITSUI NORIN CO., LTD. (JP) | 1989-06-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260020595-A1 | MOIST ORAL COMPOSITIONS | TAS2R10, TMCO1, TAS2R20 | BCL2 2456/4885KDM4E 4106/4885MAPT 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.